Evaluation of the effectiveness of Tofacitinib in rheumatoid arthritis in real clinical practice: The relationship between pain relief in the first 4 weeks and disease activity after 3–6 months
Authors:
- A. E. KarateevAKA. E. Karateev
- E. Yu. PogozhevaEPE. Yu. Pogozheva
- V. N. AmirjanovaVAV. N. Amirjanova
- E. S. FilatovaEFE. S. Filatova
- A. M. LilaALA. M. Lila
- V. I. MazurovVMV. I. Mazurov
- R. R. SamigullinaRSR. R. Samigullina
- A. M. DadalovaADA. M. Dadalova
- A. Yu. DyoADA. Yu. Dyo
- D. S. ChakievaDCD. S. Chakieva
- A. A. BaranovABA. A. Baranov
- N. A. LapkinaNLN. A. Lapkina
Open Access
- 6 September 2021
- journal article
- research article
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 59 (4) , 394–400
Abstract
The JAK inhibitor tofacitinib (TOFA) blocks the intracellular signaling pathway that activates the synthesis of cytokines and mediators involved in the development of pain and central sensitization (CS), which determines the rapid analgesic effect. However, it is not clear how pain reduction is associated with achieving low activity in rheumatoid arthritis (RA).The aim of the studywas to assess the relationship between the early clinical response to tofacitinib and a decrease in rheumatoid arthritis activity after 3 and 6 months.Material and methods.The study group consisted of 88 RA patients (age – 53±11.5 years; 79.3% of women) who received basic anti-inflammatory drugs (59.5% – methotrexate, 19.8% – leflunomide) and who were prescribed TOFA in a dose 10 mg/day. Seropositivity for rheumatoid factor was 89.8%; the value of the DAS28 index is 5.2±1.2. The severity of pain was assessed using the Brief Pain Inventory questionnaire, the neuropathic component of pain (NCP) – using the PainDETECT questionnaire, signs of CS – using the Central Sensitization Inventory (CSI) questionnaire in the early stages after the administration of TOFA, RA activity – using the DAS28-CRP index after 3 and 6 months.Results.The mean severity of pain at baseline was 5.3±2.0 on the visual analogue scale (VAS); 51.1% of patients had signs of CS (CSI>40), 15.9% had NCP (PainDETECT>18). 7 days after the start of therapy, there was a significant decrease in pain – to 4.1±1.8 according to VAS (pConclusions.The use of the JAK inhibitor TOFA allows achieving a quick analgesic effect and reducing the signs of CS. An early clinical response to TOFA (pain relief) predicts a decrease in RA activity after 3 and 6 months of therapy.Keywords
This publication has 15 references indexed in Scilit:
- JAK Inhibitors in Rheumatoid Arthritis: An Evidence-Based Review on the Emerging Clinical DataJournal of Inflammation Research, 2020
- Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-AnalysisMayo Clinic Proceedings, 2020
- A very early clinical response to treatment with the Janus kinase inhibitor tofacitinib in patients with active rheumatoid arthritis: the dynamics of pain and central sensitization elementsModern Rheumatology Journal, 2020
- The role of targeted synthetic drugs in the treatment of rheumatic diseases: focus on tofacitinibMeditsinskiy sovet = Medical Council, 2020
- Efficacy and safety of tofacitinib for immune-mediated inflammatory rheumatic diseases (Part I)Rheumatology Science and Practice, 2020
- Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitisRMD Open, 2020
- Effect of Baricitinib and Adalimumab in Reducing Pain and Improving Function in Patients with Rheumatoid Arthritis in Low Disease Activity: Exploratory Analyses from RA-BEAMJournal of Clinical Medicine, 2019
- Correlation of fatigue with other disease related and psychosocial factors in patients with rheumatoid arthritis treated with tocilizumabMedicine, 2019
- The use of routinely collected patient-reported outcome measures in rheumatoid arthritisSeminars in Arthritis and Rheumatism, 2018
- Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled TrialArthritis Care & Research, 2017